Semaglutide — GLP-1 Receptor Agonist Profile

What Is Semaglutide?

Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk. Structurally, it is a 31-amino-acid peptide analog of native glucagon-like peptide-1, engineered with a C18 fatty-acid side chain that binds albumin and extends the plasma half-life to approximately one week. That extended half-life is what enables once-weekly subcutaneous dosing (Ozempic, Wegovy) and, in a modified oral formulation with the absorption enhancer SNAC, once-daily oral dosing (Rybelsus).

Semaglutide sits at the centre of Novo Nordisk’s metabolic portfolio. It is the comparator for virtually every new GLP-1-class agent in development, and its commercial success is what funded the company’s next-generation CagriSema programme. For regulatory tracking across brands, see the Novo Nordisk pipeline overview and individual product labels.

Brand Family — Ozempic, Rybelsus, Wegovy Injection, Wegovy Pill

Semaglutide is now sold as four FDA-approved formats plus a CHMP-recommended higher-dose injection. All contain the same active molecule, but dose, route, and indication differ.

The clinically meaningful splits are now: Wegovy injection 2.4 mg for obesity (~14.9% in STEP 1), Wegovy pill 25 mg for obesity in adults who prefer oral dosing (~17% treatment-policy / 16.6% EU CHMP), the higher-dose Wegovy 7.2 mg single-dose pen (up to 20.7%, CHMP positive opinion May 22, 2026), and Ozempic up to 2.0 mg for type 2 diabetes. Off-label use of Ozempic for weight loss is widespread but produces more variable efficacy at the lower ceiling. For brand-specific guidance, see Ozempic alternatives in Dubai and Wegovy dosing and pricing in the UAE.

Mechanism of Action

Semaglutide binds and activates the GLP-1 receptor, a G-protein-coupled receptor expressed in multiple tissues. The clinically relevant effects fall into two categories:

• Central appetite regulation: GLP-1 receptor activation in the hypothalamus and brainstem suppresses appetite and reduces food intake. This is the dominant driver of weight loss in obesity populations.
• Peripheral metabolic effects: Slowed gastric emptying (which prolongs satiety and delays postprandial glucose rise), glucose-dependent insulin secretion (which improves HbA1c without causing hypoglycemia), and suppressed glucagon secretion (which reduces hepatic glucose output).

Compared with the obesity-pipeline alternatives, semaglutide’s mono-agonist architecture is the simplest GLP-1-class mechanism. It is the baseline that dual agonists (tirzepatide: GLP-1 + GIP; survodutide: GLP-1 + glucagon), combinations (CagriSema: GLP-1 + amylin), and triple agonists (retatrutide profile: GLP-1 + GIP + glucagon) are designed to exceed.

Phase 3 Programmes — STEP, SUSTAIN, SELECT, PIONEER

Semaglutide is supported by one of the most extensive Phase 3 programmes in metabolic medicine, organised into four trial families covering obesity, type 2 diabetes, cardiovascular outcomes, and oral formulation.

SELECT (2023) is semaglutide’s most strategically important post-launch readout. It established that a GLP-1 agonist can reduce cardiovascular events in adults with obesity and established cardiovascular disease, and it triggered a label expansion that no next-generation agent has yet replicated. This CV-outcomes moat is the reason semaglutide remains strategically relevant even as tirzepatide and retatrutide exceed it on weight-loss efficacy.

Efficacy Data — STEP 1 and SELECT

STEP 1 — The Pivotal Obesity Trial

STEP 1 (Wilding et al., NEJM 2021) was a 68-week, randomised, double-blind, placebo-controlled Phase 3 trial in 1,961 adults with obesity. Semaglutide 2.4 mg weekly produced approximately 14.9% mean weight loss, compared with 2.4% for placebo. The weight-loss curve remained downward-sloping at 68 weeks. STEP 1 is the dataset supporting the Wegovy obesity indication.

SELECT — Cardiovascular Outcomes

SELECT (Lincoff et al., NEJM 2023) was a cardiovascular outcomes trial in adults with overweight/obesity and established cardiovascular disease without diabetes. Semaglutide 2.4 mg weekly reduced the composite primary endpoint of major adverse cardiovascular events (MACE) by approximately 20% versus placebo. This is the first and so far only demonstration that a GLP-1 agonist reduces cardiovascular events in obesity absent type 2 diabetes, and it triggered a Wegovy label expansion for cardiovascular risk reduction.

For cross-class context, tirzepatide 15 mg produced ~22.5% weight loss in SURMOUNT-1 and retatrutide 12 mg produced ~28.7% in Phase 3 TRIUMPH-4 (December 2025) — both exceeding semaglutide on raw weight-loss efficacy. Semaglutide retains the cardiovascular-outcomes moat. For comparative analysis, see retatrutide vs tirzepatide vs CagriSema and Ozempic vs Mounjaro vs Wegovy side effects.

2026 Regulatory & Trial Headlines

Several readouts have materially shifted the semaglutide footprint since late 2025:

• Wegovy pill FDA approval (December 22, 2025): Oral semaglutide 25 mg approved for chronic weight management in adults — the first and only oral GLP-1 approved for weight loss. Treatment-policy estimate ~17% mean weight loss.
• SELECT high-FIB-4 liver substudy (Nature Medicine, April 2, 2026): A prespecified analysis in patients with FIB-4 ≥1.3 (suggesting fibrosis) found semaglutide reduced the fatty-liver index ~28% more than placebo (HR 0.72; P<0.0001) over 104 weeks and lowered cardiovascular event risk in this higher-fibrosis subgroup — extending the SELECT liver-outcomes story beyond the MASH program.
• Alcohol use disorder RCT (The Lancet, May 2, 2026): The first peer-reviewed RCT of a GLP-1 receptor agonist in treatment-seeking AUD with comorbid obesity (n=108, 26 weeks). Semaglutide cut heavy-drinking days 13.7 percentage points more than placebo (95% CI −22.0 to −5.4; p=0.0015). An emerging research signal — not an approved indication.
• EMA CHMP positive opinion on the Wegovy pill (May 22, 2026): First oral GLP-1 recommended for EU weight management. 16.6% mean weight loss; cardiovascular risk reduction supported in the dossier.
• Wegovy 7.2 mg single-dose pen CHMP positive opinion (May 22, 2026): Up to 20.7% mean weight loss — the highest figure in the semaglutide family. EU launch expected 2026.
• PIONEER TEENS (April 23, 2026): Phase 3 success for oral semaglutide in T2D adolescents 10–17. Pediatric label expansion filing expected; first oral GLP-1 with positive pediatric Phase 3 data.
• ESSENCE at EASL 2026 (May 19, 2026): Phase 3 liver-safety readout in MASH supports a favorable hepatic safety profile and reinforces the 2025 MASH approval.
• FDA 503B bulks-list proposed exclusion (April 30, 2026): Semaglutide, tirzepatide, and liraglutide proposed for permanent exclusion from the 503B bulks list — once finalised, would block outsourcing facilities from compounding these molecules off the bulks pathway.

Safety & Tolerability

Semaglutide’s safety profile is the most extensively characterised of any GLP-1 agonist. The dominant signals:

• Most common AEs: nausea, diarrhea, vomiting, constipation, abdominal pain — the canonical GLP-1-class profile. Most events are mild to moderate and concentrated in the dose-escalation phase.
• Severity: GI events typically diminish with continued exposure. Discontinuation due to AEs in STEP 1 was approximately 7% on semaglutide vs 3% on placebo.
• Pancreatitis: Rare class signal. Monitored in long-term studies. No clear dose-response established.
• Thyroid C-cell tumors: Boxed warning carried across the class based on rodent models. Human relevance remains uncertain.
• Cardiovascular safety: SELECT demonstrated reduced MACE; no cardiovascular safety signal has emerged in the large Phase 3 dataset.
• NAION (eye signal): The UK MHRA Drug Safety Update (February 5, 2026), aligned with the EMA PRAC review, concluded that non-arteritic anterior ischaemic optic neuropathy is a very rare side effect of semaglutide medicines — approximately 1 additional case per 10,000 patient-years and ~2× relative risk versus untreated type 2 diabetes. SmPC/PIL labelling updates were issued.

For focused breakdowns, see side-effects comparison, Ozempic face — facial fat loss, and GLP-1 muscle loss and body composition. For the pre-treatment workup — HbA1c, CMP, lipids, thyroid history, and lipase context — see the blood tests before GLP-1s checklist.

How It Compares — Semaglutide vs Next-Generation Agents

Semaglutide is the benchmark. Every next-generation obesity candidate is designed and evaluated relative to it. The consistent pattern across head-to-head and cross-trial comparisons is that adding receptor arms delivers incremental weight-loss efficacy:

• vs Tirzepatide: Tirzepatide (GLP-1/GIP dual agonist) produced ~22.5% at 72 weeks in SURMOUNT-1 vs semaglutide’s ~14.9% in STEP 1. STEP 8 confirmed the gap in head-to-head design.
• vs Retatrutide profile: Triple agonist (GLP-1/GIP/glucagon) produced ~28.7% at 68 weeks in Phase 3 TRIUMPH-4 (December 2025). The glucagon arm adds energy-expenditure mechanics semaglutide lacks.
• vs CagriSema: Semaglutide + cagrilintide co-formulation produced ~22.7% at 68 weeks in REDEFINE 1 — but failed non-inferiority vs tirzepatide 15 mg in REDEFINE 4.
• vs Orforglipron: Oral non-peptide GLP-1 agonist with Phase 3 obesity weight loss in the mid-teens percent range — comparable to semaglutide’s injectable, with oral convenience as the differentiator.

Semaglutide’s strategic moat is its CV-outcomes label (SELECT), its massive real-world safety dataset, and payer familiarity. Its weight-loss ceiling is now permanently exceeded by dual and triple agonists.

Research Use Notes

Semaglutide as a research-grade reference standard is proprietary to Novo Nordisk. Remy Peptides does not supply semaglutide. Laboratories working on GLP-1 receptor pharmacology typically reference published SUSTAIN and STEP data, the Novo Nordisk clinical pharmacology dossiers, and class-adjacent research peptides.

For laboratories characterising next-generation obesity mechanisms, Remy Peptides supplies HPLC-verified retatrutide pens (Janoshik Analytical Batch RETP002, 99.262% purity). Retatrutide is the unimolecular triple agonist that sits at the mechanistic opposite of semaglutide — three receptors in one molecule versus one — making it the logical next-generation reference for comparative GLP-1-class work. See the retatrutide in Dubai guide for full laboratory context.

All Remy Peptides products are supplied for in-vitro laboratory research only. Not for human or veterinary use. UAE MoHAP Circular 17/2022 compliance statement.